Veracyte, Inc. VCYT
$44.19
-4.02%
at last close
Market Cap$3.70 billion
P/E Ratio31.56
Div Yield—
Volume1.43M
52-Week Range
$28.55$60.91
Analyst Ratings
- Consensus
- Moderate Buy — 7 Buy · 1 Hold · 1 Sell (9 analysts)
- Avg. Price Target
- $57.00 (+29.0% upside)
Key Stats
- Today's Range
- $44.18 – $47.14
- 50-Day Range
- $38.24 – $59.96
- 52-Week Range
- $28.55 – $60.91
- Volume
- 1.43 million shs
- Average Volume
- 1.42 million shs
- Market Cap
- $3.70 billion
- P/E Ratio
- 31.56
- Dividend Yield
- —
Valuation
- P/E Ratio
- 31.56
- Price / Book
- 2.67
- Price / Sales
- 6.59
Short Interest
- Short Interest
- 0.83%
- Days to Cover
- 3.44
Financials (TTM)
- Revenue
- $561.90 million
- Net Income
- $114.48 million
- Net Margin
- 20.37%
- Return on Equity
- 8.25%
- Debt-to-Equity
- —
About Veracyte, Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Related Stocks
Compare head-to-head: VCYT vs NTRA·VCYT vs DGX·VCYT vs CAI·VCYT vs GRAL
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.